Flag of the European Union EU Clinical Trials Register Help

Clinical trials for Motor Neuron Disease

The European Union Clinical Trials Register   allows you to search for protocol and results information on:
  • interventional clinical trials that were approved in the European Union (EU)/European Economic Area (EEA) under the Clinical Trials Directive 2001/20/EC
  • clinical trials conducted outside the EU/EEA that are linked to European paediatric-medicine development

    • EU/EEA interventional clinical trials approved under or transitioned to the Clinical Trial Regulation 536/2014 are publicly accessible through the
    Clinical Trials Information System (CTIS).

    The EU Clinical Trials Register currently displays   44346   clinical trials with a EudraCT protocol, of which   7374   are clinical trials conducted with subjects less than 18 years old.   The register also displays information on   18700   older paediatric trials (in scope of Article 45 of the Paediatric Regulation (EC) No 1901/2006).

    Phase 1 trials conducted solely on adults and that are not part of an agreed paediatric investigation plan (PIP) are not publicly available (see Frequently Asked Questions ).  
     
    Examples: Cancer AND drug name. Pneumonia AND sponsor name.
    How to search [pdf]
    Search Tips: Under advanced search you can use filters for Country, Age Group, Gender, Trial Phase, Trial Status, Date Range, Rare Diseases and Orphan Designation. For these items you should use the filters and not add them to your search terms in the text field.
    Advanced Search: Search tools
     
    189 result(s) found for: Motor Neuron Disease. Displaying page 2 of 10.
    « Previous 1  2  3  4  5  6  7  8  9  Next» Last»»
    EudraCT Number: 2020-000376-38 Sponsor Protocol Number: MT-1186-A03 Start Date*: 2021-03-22
    Sponsor Name:Mitsubishi Tanabe Pharma Development America, Inc.
    Full Title: A Phase 3, Multi-center, Open-label, Safety Extension Study of Oral Edaravone Administered over 96 Weeks in Subjects with Amyotrophic Lateral Sclerosis (ALS)
    Medical condition: Amyotrophic Lateral Sclerosis (ALS)
    Disease: Version SOC Term Classification Code Term Level
    21.1 10029205 - Nervous system disorders 10002026 Amyotrophic lateral sclerosis PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: FR (Completed) DE (Completed) IT (Completed)
    Trial results: View results
    EudraCT Number: 2020-005193-94 Sponsor Protocol Number: WVE-004-001 Start Date*: 2021-12-20
    Sponsor Name:Wave Life Sciences UK Limited
    Full Title: A Multicenter, Randomized, Double-blind, Placebo-controlled, Phase 1b/2a Study of WVE-004 Administered Intrathecally to Patients with C9orf72-associated Amyotrophic Lateral Sclerosis (ALS) or Front...
    Medical condition: Amyotrophic Lateral Sclerosis and Frontotemporal Dementia
    Disease: Version SOC Term Classification Code Term Level
    21.1 10029205 - Nervous system disorders 10002026 Amyotrophic lateral sclerosis PT
    21.1 10029205 - Nervous system disorders 10068968 Frontotemporal dementia PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Completed) NL (Completed) IE (Completed) SE (Completed) BE (Completed)
    Trial results: View results
    EudraCT Number: 2015-005347-14 Sponsor Protocol Number: H2020/PHRC-N/2014/GB-01 Start Date*: 2016-08-25
    Sponsor Name:CHU DE NIMES
    Full Title: Efficacy and safety of low-dose IL-2 (ld-IL-2) as a Treg enhancer for controlling neuro-inflammation in newly diagnosed Amyotrophic Lateral Sclerosis (ALS) patients: A randomized, double-blind, pla...
    Medical condition: Amyotrophic Lateral Sclerosis (ALS)
    Disease: Version SOC Term Classification Code Term Level
    20.0 10029205 - Nervous system disorders 10002026 Amyotrophic lateral sclerosis PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GB (GB - no longer in EU/EEA)
    Trial results: (No results available)
    EudraCT Number: 2012-002099-15 Sponsor Protocol Number: APOCT-001 Start Date*: 2014-09-15
    Sponsor Name:Apodemus AB
    Full Title: A randomised, double blind, placebo controlled trial to evaluate the safety and efficacy of Apovir for treatment of patients with Amyotrophic lateral sclerosis
    Medical condition: Amyotrophic Lateral Sclerosis (ALS)
    Disease: Version SOC Term Classification Code Term Level
    17.0 10029205 - Nervous system disorders 10002026 Amyotrophic lateral sclerosis PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: SE (Prematurely Ended)
    Trial results: (No results available)
    EudraCT Number: 2015-005810-31 Sponsor Protocol Number: MD1003CT2015-02-ALS Start Date*: 2016-06-03
    Sponsor Name:MEDDAY PHARMACEUTICALS
    Full Title: Effect of MD1003 in amyotrophic lateral sclerosis: a randomized, double blind placebo controlled study
    Medical condition: Amyotrophic lateral sclerosis
    Disease: Version SOC Term Classification Code Term Level
    19.0 10029205 - Nervous system disorders 10002026 Amyotrophic lateral sclerosis PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: FR (Completed)
    Trial results: View results
    EudraCT Number: 2021-003900-42 Sponsor Protocol Number: MT-1186-A04 Start Date*: 2022-07-15
    Sponsor Name:Mitsubishi Tanabe Pharma America, Inc. (MTPA)
    Full Title: A Phase 3b, Multicenter, Randomized, Double-blind Extension Study to Evaluate the Continued Efficacy and Safety of Oral Edaravone Administered for an Additional Period of up to 48 Weeks Following S...
    Medical condition: Amyotrophic Lateral Sclerosis (ALS)
    Disease: Version SOC Term Classification Code Term Level
    21.1 10029205 - Nervous system disorders 10002026 Amyotrophic lateral sclerosis PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Prematurely Ended) IT (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2008-002110-22 Sponsor Protocol Number: LTA-2-2008 Start Date*: 2008-09-16
    Sponsor Name:Prof. dr L.H. van den Berg, UMC-Utrecht
    Full Title: A randomised sequential trial of Lithium in amyotrophic lateral sclerosis
    Medical condition: Amyotrophic lateral sclerosis (ALS) is a disease characterised by progressive degeneration of motor neurons in brain and spinal cord leading to muscle weakness. ALS can occur at anytime in adulthoo...
    Disease: Version SOC Term Classification Code Term Level
    9.1 10052889 ALS LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: NL (Completed)
    Trial results: View results
    EudraCT Number: 2021-004727-33 Sponsor Protocol Number: CY5032 Start Date*: 2022-10-28
    Sponsor Name:Cytokinetics Inc
    Full Title: A Phase 3, Open-Label Extension of COURAGE-ALS (CY 5031)
    Medical condition: Amyotrophic Lateral Sclerosis (ALS)
    Disease: Version SOC Term Classification Code Term Level
    21.1 10029205 - Nervous system disorders 10002026 Amyotrophic lateral sclerosis PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: IE (Prematurely Ended) BE (Completed) NL (Prematurely Ended) SE (Prematurely Ended) FR (Prematurely Ended) IT (Prematurely Ended) ES (Prematurely Ended) PT (Ongoing) DK (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2021-000325-26 Sponsor Protocol Number: ANX005-ALS-01 Start Date*: 2021-04-29
    Sponsor Name:Annexon Biosciences
    Full Title: Phase 2a Safety, Tolerability, Pharmacokinetic, and Pharmacodynamic Study of Intravenous ANX005 in Subjects with Amyotrophic Lateral Sclerosis
    Medical condition: Amyotrophic Lateral Scelrosis (ALS)
    Disease: Version SOC Term Classification Code Term Level
    21.1 10029205 - Nervous system disorders 10002026 Amyotrophic lateral sclerosis PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: FR (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2012-004987-23 Sponsor Protocol Number: CY4026 Start Date*: 2013-02-08
    Sponsor Name:Cytokinetics Inc
    Full Title: A Phase IIb, multi-national, double-blind, randomised, placebo-controlled study to evaluate the safety, tolerability and efficacy of CK-2017357 in patients with amyotrophic lateral sclerosis (ALS)
    Medical condition: Amyotrophic lateral sclerosis
    Disease: Version SOC Term Classification Code Term Level
    14.1 10029205 - Nervous system disorders 10002026 Amyotrophic lateral sclerosis PT
    Population Age: Adults Gender: Male, Female
    Trial protocol: IE (Completed) GB (Completed) DE (Completed) NL (Completed) ES (Completed)
    Trial results: View results
    EudraCT Number: 2006-005410-13 Sponsor Protocol Number: GERP ALS Start Date*: 2008-04-22
    Sponsor Name:University Hospital of Ulm
    Full Title: EFFICACY, SAFETY AND TOLERABILITY STUDY OF 45 mg PIOGLITAZONE IN PATIENTS WITH AMYOTROPHIC LATERAL SCLEROSIS (ALS) RECEIVING STANDARD THERAPY (RILUZOLE).
    Medical condition: Male or female adult patients with amyotrophic lateral sclerosis (ALS) accoring to the El Escorial Criteria for the diognosis of ALS and treated for at least 3 month with 100 mg riluzole (standard ...
    Disease: Version SOC Term Classification Code Term Level
    9.1 10002026 Amyotrophic lateral sclerosis LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Prematurely Ended)
    Trial results: (No results available)
    EudraCT Number: 2008-001094-15 Sponsor Protocol Number: LitALS Start Date*: 2008-03-10
    Sponsor Name:AZIENDA SANITARIA OSPEDALIERA "S. GIOVANNI BATTISTA DI TORINO"
    Full Title: SINGLE-BLIND, RANDOMIZED, PARALLEL GROUP, DOSE-FINDING TRIAL ON LITHIUM FOR THE TREATMENT OF AMYOTROPHIC LATERAL SCLEROSIS (ALS)
    Medical condition: ALS patient according with the El-Escorial criteria
    Disease: Version SOC Term Classification Code Term Level
    9.1 10002026 Amyotrophic lateral sclerosis LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: IT (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2007-002379-16 Sponsor Protocol Number: 2007-002379-16 Start Date*: 2007-05-29
    Sponsor Name:I.N.M. NEUROMED (I.R.C.C.S.) S.R.L. GIA' SANATRIX
    Full Title: MULTICENTER TRIAL (SINGLE BLIND)VS ON THE EFFICACY OF LITHIUM SALTS +RILUZOLE VS PLACEBO+RILUZOLE IN PATIENTS AFFECTED BY AMYOTROPHIC LATERAL SCLEROSIS
    Medical condition: Patients affected by amyotrophic lateral sclerosis (ALS)
    Disease: Version SOC Term Classification Code Term Level
    6.1 10002026 PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: IT (Prematurely Ended)
    Trial results: (No results available)
    EudraCT Number: 2004-004158-23 Sponsor Protocol Number: 3303 Start Date*: 2005-04-15
    Sponsor Name:IST. DI RICERCHE FARMACOLOG. M. NEGRI
    Full Title: DOUBLE-BLIND PLACEBO-CONTROLLED TRIAL ON THE USE OF ACETYL-L-CARNITINE FOR THE TREATMENT OF AMYOTROPHIC LATERAL SCLEROSIS (ALS)
    Medical condition: Amyotrophic lateral sclerosis therapy
    Disease: Version SOC Term Classification Code Term Level
    9.1 10002026 Amyotrophic lateral sclerosis LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: IT (Completed)
    Trial results: View results
    EudraCT Number: 2011-004482-32 Sponsor Protocol Number: RAS-ALS Start Date*: 2013-04-10
    Sponsor Name:Universitätsklinikum Ulm
    Full Title: Efficacy, Safety and Tolerability Study of 1 mg Rasagiline in Patients with Amyotrophic Lateral Sclerosis (ALS) Receiving Standard Therapy (Riluzole)
    Medical condition: Amyotrophic Lateral Sclerosis (ALS)
    Disease: Version SOC Term Classification Code Term Level
    14.1 10029205 - Nervous system disorders 10002026 Amyotrophic lateral sclerosis PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Completed)
    Trial results: View results
    EudraCT Number: 2007-001592-10 Sponsor Protocol Number: TUDCA 20071 Start Date*: 2008-02-15
    Sponsor Name:ISTITUTO NEUROLOGICO "CARLO BESTA"
    Full Title: A randomized, double-blind pilot study vs. placebo for the evaluation of efficacy and tolerability of tauroursodeoxycholic acid administered by oral route as add on treatment in patients affected b...
    Medical condition: AMYOTROPHIC LATERAL SCLEROSIS
    Disease: Version SOC Term Classification Code Term Level
    9.1 10002026 Amyotrophic lateral sclerosis LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: IT (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2008-006722-34 Sponsor Protocol Number: SLA_Litio Start Date*: 2009-06-23
    Sponsor Name:ISTITUTO SUPERIORE DI SANITA`
    Full Title: Multicentric randomized placebo controlled trial of Lithium carbonate combined with Riluzole in patients with ALS
    Medical condition: Amyotrophic Lateral Sclerosis
    Disease: Version SOC Term Classification Code Term Level
    9.1 10002026 Amyotrophic lateral sclerosis LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: IT (Prematurely Ended)
    Trial results: (No results available)
    EudraCT Number: 2011-001329-26 Sponsor Protocol Number: EPOSS2010 Start Date*: 2011-08-03
    Sponsor Name:ISTITUTO NEUROLOGICO "CARLO BESTA"
    Full Title: ErythroPOietin in ALS: a Study of dose-finding and Safety
    Medical condition: Amyotrophic Lateral Sclerosis
    Disease: Version SOC Term Classification Code Term Level
    14.0 10029205 - Nervous system disorders 10002026 Amyotrophic lateral sclerosis PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: IT (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2016-002399-28 Sponsor Protocol Number: RAP-ALS Start Date*: 2017-07-14
    Sponsor Name:AZIENDA OSPEDALIERO-UNIVERSITARIA POLICLINICO DI MODENA
    Full Title: Rapamycin (Sirolimus) treatment for amyotrophic lateral sclerosis
    Medical condition: definite or probable ALS
    Disease: Version SOC Term Classification Code Term Level
    20.0 10029205 - Nervous system disorders 10002026 Amyotrophic lateral sclerosis PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: IT (Completed)
    Trial results: (No results available)
    EudraCT Number: 2007-004723-37 Sponsor Protocol Number: ONO-2506POE015 Start Date*: 2008-05-16
    Sponsor Name:ONO Pharmaceutical Co., Ltd.
    Full Title: A Phase II multi-centre, extension study to investigate the long term safety of ONO-2506PO in patients diagnosed with Amyotrophic Lateral Sclerosis (ALS).
    Medical condition: Amyotrophic Lateral Sclerosis (ALS)
    Disease: Version SOC Term Classification Code Term Level
    9.1 10002026 Amyotrophic lateral sclerosis LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Prematurely Ended) BE (Completed) FR (Completed) GB (Prematurely Ended)
    Trial results: View results
    Download Options:
    Number of Trials to download:
    Download Content:
    Download Format:
    Note, where multi-state trials are shown in search results, selecting "Full Trial details" will download full information for each of the member states/countries involved in the trial.
    « Previous 1  2  3  4  5  6  7  8  9  Next» Last»»
    Query did not match any studies.
    For support, Contact us.
    The status and protocol content of GB trials is no longer updated since 1 January 2021. For the UK, as of 31 January 2021, EU Law applies only to the territory of Northern Ireland (NI) to the extent foreseen in the Protocol on Ireland/NI. Legal notice
    As of 31 January 2023, all EU/EEA initial clinical trial applications must be submitted through CTIS . Updated EudraCT trials information and information on PIP/Art 46 trials conducted exclusively in third countries continues to be submitted through EudraCT and published on this website.

    European Medicines Agency © 1995-Sun Jun 29 03:18:34 CEST 2025 | Domenico Scarlattilaan 6, 1083 HS Amsterdam, The Netherlands
    EMA HMA